Acción·LSE·£
Axsome Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative treatments for central nervous system (CNS) disorders, primarily focusing on the United States market. Its pipeline includes AXS-05, a therapeutic candidate for major depressive disorder and treatment-resistant depression, which is also currently in Phase III clinical trials for Alzheimer's disease agitation and has completed Phase II studies for smoking cessation. The company is also advancing AXS-07, an experimental, rapidly absorbed, oral medication with a multi-mechanistic profile, which has successfully concluded two Phase III trials for the acute treatment of migraine. Another key asset is AXS-12, a selective and potent norepinephrine reuptake inhibitor, presently in Phase III development for narcolepsy. Furthermore, AXS-14, an investigational oral medicine, is undergoing Phase III trials for fibromyalgia. Axsome Therapeutics maintains a research collaboration with Duke University to further evaluate AXS-05 for smoking cessation. The company was founded in 2012 and is headquartered in New York, New York.
Ve el precio de 0HKF.L en vivo en tu pantalla física de escritorio. Configura alertas con las apps iOS y Android.
